Potentiating Antibody Therapy for the Treatment of Cancer
Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense
The technology focuses on the development of a tetravalent bispecific antibody effective against Bacillus anthracis, the bacterium responsible for anthrax. This antibody combines the specificities of two monoclonal antibodies (mAbs): one targeting anthrax protective antigen (PA) and the other targeting the bacterial capsule. The anti-PA mAb shows potent toxin-neutralizing activity, while the anti-capsule mAb efficiently kills anthrax bacteria.
Chimeric Antibodies Against Hepatitis B e-Antigen
A Novel Rapid Point-of Care Diagnostic Method for Infectious and Autoimmune Diseases
Polyclonal Antibodies to Apolipoprotein L1 for Use in Basic Science Research
Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus)
CDC NIOSH researchers have developed a simple and rapid detection technique for Stachybotrys chartarum (a type of mold that commonly grows on wet building materials) by producing monoclonal antibodies which reacts with proteins in Stachybotrys chartarum. These antibodies can be used in immunologic detection assays to detect and possibly quantify Stachybotrys chartarum in environmental samples, and to our knowledge, they do not cross react with other fungi.
Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis
Monoclonal Antibodies That Bind to the Underside of Influenza Viral Neuraminidase
Current influenza vaccines mainly induce antibodies against the surface glycoprotein hemagglutinin (HA) that block viral attachment to its host receptors and viral membrane fusion to the host cell. The immunodominant head region of HA undergoes antigenic drift and antibodies directed to the head confer little cross-protections between strains or subtypes.